WASHINGTON — In the final hours of a lame-duck Congress, lawmakers on Wednesday confirmed the Trump administration’s nominees for science adviser and “drug czar,” following nearly two years in which those White House posts sat vacant.
The confirmation of Kelvin Droegemeier, a former University of Oklahoma professor, means the White House’s Office of Science and Technology Policy will have a director for the first time since the president’s inauguration in January 2017. Droegemeier, a meteorologist, has received largely positive reviews from the scientific community at large, including from John Holdren, the OSTP director during the Obama administration.
About the Author Reprints
My frustration continues to grow daily at the attacks on the drug industry. I have told friends & family alike the next time your child is ill–decline that antibiotic. When grandma is diagnosed with Parkinson’s—deal with it. Those migraines that are your weekly burden,you are on your OWN. This 21st century has no idea the blessing we have in the intellect,work ethic and skill of the pharmaceutical industry members.
True, many advances in medicine have come along, that does not allow for greed & avarice to become acceptable when certain Big Pharma promote drugs to only increase the bottom line.